Associated Papers
Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients.
Richman J et al.
Breast Cancer Research and Treatment, 2024
38709373 (PubMed )
Supplement: 10549_2024_7311_MOESM2_ESM.xlsx › Suppl_Table_5
Characterizing multi-PIK3CA mutations across cancer types: Toward precision oncology.
Nakamura K et al.
Cancer Medicine, 2024
39054873 (PubMed )
Supplement: CAM4-13-e70052-s002.xlsx › Table_S2
PIK3CA mutations in endocrine-resistant breast cancer.
Schagerholm C et al.
Scientific Reports, 2024
38822093 (PubMed )
Supplement: 41598_2024_62664_MOESM1_ESM.pdf
ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.
Chen JW et al.
Molecular Oncology, 2023
36892268 (PubMed )
Supplement: MOL2-17-2000-s008.pdf
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers.
Hutchinson KE et al.
Genome Medicine, 2023
37101291 (PubMed )
Supplement: 13073_2023_1181_MOESM1_ESM.pdf
Uterine lavage identifies cancer mutations and increased TP53 somatic mutation burden in individuals with ovarian cancer.
Ghezelayagh TS et al.
Cancer Research Communications, 2022
36311816 (PubMed )
Supplement: crc-22-0314-s02.xlsx › Table_S6_List_of_mutations
Distinct Genomic Profiles Are Associated with Treatment Response and Survival in Ovarian Cancer.
de Witte CJ et al.
Cancers, 2022
35326660 (PubMed )
Supplement: cancers-14-01511-s001.zip › Supplemenatry_Tables_1_to_8.xlsx › TableS7_Actionability
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.
Pascual J et al.
Cancer Discovery, 2021
Frequent FOXA1-Activating Mutations in Extramammary Paget's Disease.
Takeichi T et al.
Cancers, 2020
32235312 (PubMed )
Supplement: cancers-12-00820-s001.pdf
Analysis on GENIE reveals novel recurrent variants that affect molecular diagnosis of sizable number of cancer patients.
Koyama T et al.
Bmc Cancer, 2019
30709382 (PubMed )
Supplement: 12885_2019_5313_MOESM2_ESM.xlsx › supplementary_2_filtered
Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients.
Wong SQ et al.
British Journal of Cancer, 2015
25742471 (PubMed )
Supplement: bjc201580x7.xls › Supp_Table_3
Select a paper to view details